INTESTINAL-ABSORPTION IN PATIENTS WITH RHEUMATOID-ARTHRITIS TREATED WITH METHOTREXATE

被引：10

作者：

PHELAN, MJI

TAYLOR, W

VANHEYNINGEN, C

WILLIAMS, E

THOMPSON, RN

机构：

[1] Rheumatology Unit, Fazakerley Hospital, Liverpool, L9 7AL, Longmoor Lane

来源：

CLINICAL RHEUMATOLOGY | 1993年 / 12卷 / 02期

关键词：

MALABSORPTION; D-XYLOSE; METHOTREXATE; ARTHRITIS; DUODENAL BIOPSY;

D O I：

10.1007/BF02231531

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Twelve patients with rheumatoid arthritis treated for at least 12 months with methotrexate and 11 matched rheumatoid arthritis controls underwent a standard d-xylose absorption test. No patients had any pre-existing clinical of biochemical evidence of malabsorption. No significant difference was observed in the 1 hour plasma d-xylose estimation between methotrexate treated patients and controls. The 2 to 5 hour urinary excretion ratio, however, was significantly lower in the methotrexate-treated group compared with controls indicating a minor degree of malabsorption. Six of the methotrexate treated patients and 5 of the controls underwent endoscopic duodenal biopsy but neither group demonstrated any significant histological changes. In conclusion, methotrexate therapy in patients with rheumatoid arthritis produces mild intestinal malabsorption.

引用

页码：223 / 225

页数：3

共 15 条

[1]

Thompson R.N., Watts C., Edelman J., Esdaile J., Russell A.S., A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis, J Rheumatol, 11, pp. 760-3, (1984)

[2]

Kremer J.M., Lee J.K., The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis, Arthritis Rheum, 29, pp. 822-31, (1986)

[3]

Alarcon G.S., Tracy I.C., Blackburn W.D., Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment, Arthritis Rheum, 32, pp. 671-6, (1989)

[4]

Croft A.W., Kay H.E.M., Lawson, Methotrexate-induced malabsorption in children with acute lymphoblastic leukaemia, BMJ, 2, pp. 1511-2, (1977)

[5]

Baird G.M., Dossetor J.F.B., Methotrexate enteropathy, Lancet, 1, (1981)

[6]

Pinkerton C.R., Glasgow J.F.T., Methotrexate enteropathy?, Lancet, 1, (1981)

[7]

Pinkerton C.R., Cameron C.H.S., Sloan J.M., Glasgow J.F.T., Gwevava N.J.T., Jejunal crypt cell abnormalities associated with methotrexate treatment in children with acute lymphoblastic leukaemia, J Clin Pathol, 35, pp. 1272-7, (1982)

[8]

Gwevava N.J.T., Pinkerton C.R., Glasgow J.F.T., Sloan J.M., Bridges J.M., Small bowel enterocyte abnormalities caused by methotrexate treatment in acute lymphoblastic leukaemia, Journal of Clinical Pathology, 34, pp. 790-5, (1981)

[9]

Trier J.S., Morphological alterations induced by methotrexate in the mucosa of human proximal intestine, Gasteroenterology, 42, pp. 295-304, (1962)

[10]

Arnett F.C., Edworthy S.M., Bloch D.A., Et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum, 31, pp. 315-24, (1988)

← 1 2 →